Clinical trial · Interventional
Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast
Evaluation of Renal Masses Using Ultrasound Intravenous Microbubble Contrast
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate the blood flow in kidney masses by using ultrasound microbubble contrast material, and to see if results from ultrasound contrast studies can predict if a kidney mass is benign or malignant. Patterns of blood flow in the kidney mass will be examined to see if: 1. benign kidney masses can be distinguished from kidney cancers and 2. if slow growing, lower risk cancers have different blood flow compared to clear cell cancer which is the most common type of kidney cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
| Renal Cancer | Kidney Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ultrasound with intravenous microbubble contrast injection | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- Patients entering into this protocol will also have a preoperative renal contrast enhanced US for this research study. Renal mass US contrast enhancement results will be compared with surgical pathological findings to determine if contrast enhancement patterns of the renal masses correlate with benign and malignant histopathology, and/or malignant histologic subtype.
- interventionNames
- Drug: Ultrasound with intravenous microbubble contrast injection
Primary outcomes (1)
- measure
- To determine the accuracy of contrast enhanced ultrasound of renal masses to predict benign vs. malignant histology
- timeFrame
- conclusion of study
Secondary outcomes (2)
- measure
- To determine if clear cell renal malignancies can be predicted, or differentiated, from other less aggressive malignant subtypes, based on analysis of the data.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Any adult patient who is planned or scheduled for surgical excision or biopsy of a solid or complex cystic renal mass would be eligible for the study * Histology of the renal mass must be unknown at the time of enrollment * Patients who have renal masses that are evident on conventional US imaging * Patients will have a correlative abdominal CT and/or MRI Exclusion Criteria: * Patients with any history of cardiac shunts. * Patients with history of pulmonary hypertension or unstable cardiopulmonary conditions, including patients on mechanical ventilation. * Patients without peripheral IV access * Pregnant patients and children * Patients with any known contrast allergies, allergy to perflutren, or any components of Definity or microbubble contrast * Patients who have renal masses that are not evident on conventional US imaging
References
Publications (0)
Data not yet available